Biomarin Pharmaceutical (BMRN) Other Working Capital Changes (2016 - 2025)
Biomarin Pharmaceutical's Other Working Capital Changes history spans 17 years, with the latest figure at -$41.0 million for Q4 2025.
- For the quarter ending Q4 2025, Other Working Capital Changes fell 153.8% year-over-year to -$41.0 million, compared with a TTM value of -$8.9 million through Dec 2025, down 335.34%, and an annual FY2025 reading of -$8.9 million, down 335.34% over the prior year.
- Other Working Capital Changes for Q4 2025 was -$41.0 million at Biomarin Pharmaceutical, down from $17.0 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $36.0 million in Q1 2023, with the low at -$42.8 million in Q1 2021.
- Average Other Working Capital Changes over 5 years is $382000.0, with a median of $6.1 million recorded in 2023.
- Year-over-year, Other Working Capital Changes crashed 499.78% in 2022 and then skyrocketed 349.39% in 2023.
- Tracing BMRN's Other Working Capital Changes over 5 years: stood at -$2.7 million in 2021, then crashed by 499.78% to -$16.4 million in 2022, then surged by 44.73% to -$9.1 million in 2023, then crashed by 78.5% to -$16.2 million in 2024, then plummeted by 153.8% to -$41.0 million in 2025.
- Per Business Quant, the three most recent readings for BMRN's Other Working Capital Changes are -$41.0 million (Q4 2025), $17.0 million (Q3 2025), and $8.8 million (Q2 2025).